


## Mito-TEMPO

<b>Cat. No.:</b>	HY-112879
<b>CAS No.:</b>	1334850-99-5
<b>Molecular Formula:</b>	C <sub>29</sub> H <sub>35</sub> ClN <sub>2</sub> O <sub>2</sub> P
<b>Molecular Weight:</b>	510.03
<b>Target:</b>	Mitochondrial Metabolism; Reactive Oxygen Species
<b>Pathway:</b>	Metabolic Enzyme/Protease; Immunology/Inflammation; NF-κB
<b>Storage:</b>	-20°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 125 mg/mL (245.08 mM; Need ultrasonic)					
	H <sub>2</sub> O : 60 mg/mL (117.64 mM; Need ultrasonic)					
	<b>Preparing Stock Solutions</b>	<b>Solvent</b>	<b>Mass</b>	<b>1 mg</b>	<b>5 mg</b>	<b>10 mg</b>
		<b>Concentration</b>				
		<b>1 mM</b>		1.9607 mL	9.8033 mL	19.6067 mL
<b>5 mM</b>			0.3921 mL	1.9607 mL	3.9213 mL	
	<b>10 mM</b>		0.1961 mL	0.9803 mL	1.9607 mL	
Please refer to the solubility information to select the appropriate solvent.						
<b>In Vivo</b>	1. Add each solvent one by one: PBS Solubility: 50 mg/mL (98.03 mM); Clear solution; Need ultrasonic					
	2. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.25 mg/mL (4.41 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.25 mg/mL (4.41 mM); Clear solution					
	4. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.25 mg/mL (4.41 mM); Clear solution					

### BIOLOGICAL ACTIVITY

<b>Description</b>	Mito-TEMPO is a mitochondria-targeted superoxide dismutase mimetic with superoxide and alkyl radical scavenging properties <sup>[1]</sup> .
<b>In Vivo</b>	Mito-TEMPO (MT) greatly attenuates the increase in ALT activities and reduces the areas of necrosis at both time points, indicating that the protection by Mito-TEMPO is sustained until at least 24 h post-APAP. Mito-Tempo could induce secondary apoptosis in the late phase of APAP hepatotoxicity. Mito-Tempo induces secondary apoptosis after APAP overdose by

inhibition of RIP3<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## PROTOCOL

### Animal

#### Administration <sup>[1]</sup>

Mice<sup>[1]</sup>

Male C57BL/6J mice (8-12 weeks) and RIP3-deficient mice (C57BL/6N background) are used throughout the study. The mice are acclimated before experiments with free access to diet and water. Overnight-fasted mice (16-18 h) are treated i.p. with 300 mg/kg APAP dissolved in warm saline. Some mice are treated with 200 mg/kg APAP in experiments evaluating effect of RIP3 deficiency. A dose of 20 mg/kg Mito-Tempo dissolved in saline is administered i.p. 1.5 or 3 h after APAP. Some mice are subsequently treated (i.p.) with 10 mg/kg ZVD fmk dissolved in Tris-buffered saline or vehicle 2 h after APAP. To mimic the clinical care of APAP-overdose patients, some mice receive the antidote NAC (i.p., 500 mg/kg) at 1.5 or 3 h after APAP overdose<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## CUSTOMER VALIDATION

- Nat Commun. 2023 Feb 16;14(1):872.
- Adv Sci (Weinh). 2023 Feb 3;e2207084.
- Acta Pharm Sin B. 21 July 2021.
- J Hazard Mater. 2023 Jun 1, 131750.
- J Hazard Mater. 15 February 2022, 127268.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

[1]. Du K, et al. Mito-tempo protects against acute liver injury but induces limited secondary apoptosis during the late phase of acetaminophen hepatotoxicity. Arch Toxicol. 2018 Oct 15.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA